| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2023―Sep―18 |
Effects of Renin-Angiotensin system blockers on outcomes from COVID-19: A systematic review and meta-analysis of randomised controlled trials |
Matthew M Y Lee, Toru Kondo, Ross T Campbell, Mark C Petrie, Naveed Sattar, Scott D Solomon, et al. (+3) Muthiah Vaduganathan, Pardeep S Jhund, John J V McMurray |
| 2 |
[GO] |
2023―Mar―15 |
Sex-based differences in risk of ischemic stroke or systemic embolism after BNT162b2 or CoronaVac COVID-19 vaccination in patients with atrial fibrillation: A self-controlled case series and nested case-control study |
Xuxiao Ye, Caige Huang, Vincent K C Yan, Wei Kang, Min Fan, Gigi K C Tsang, et al. (+15) Clarissa M Y Ho, Gregory Y H Lip, Kai-Hang Yiu, Hung-Fat Tse, Tiantian Ma, Xiwen Qin, Celine S L Chui, Francisco T T Lai, Carlos K H Wong, Eric Y F Wan, Xue Li, Cheuk Kwong Lee, Ivan F N Hung, Ian C K Wong, Esther W Chan |
| 3 |
[GO] |
2023―Feb―01 |
Corrigendum to: Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis |
|
| 4 |
[GO] |
2022―Aug―14 |
Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis |
Giulia Ferrannini, Lars H Lund, Lina Benson, Manfredi Rizzo, Wael Almahmeed, Giuseppe M C Rosano, et al. (+2) Gianluigi Savarese, Francesco Cosentino |
| 5 |
[GO] |
2022―Mar―14 |
Neuraminidase inhibitor treatment is associated with decreased mortality in COVID-19 patients: a retrospective analysis |
Junfang Wu, Mingming Zhao, Haoran Wei, Chenze Li, Dong Hu, Lemin Zheng, Dao Wen Wang |
| 6 |
[GO] |
2022―Feb―17 |
Repurposing low-dose naltrexone (LDN) for the prevention and treatment of immunothrombosis in COVID-19 |
Bertram Pitt, Ashley M Tate, David Gluck, Robert S Rosenson, Sascha N Goonewardena |
| 7 |
[GO] |
2022―Jan―29 |
Thromboprophylaxis for COVID-19-related coagulopathy: what next? |
Viktor Čulić, Riccardo Vio, Riccardo Proietti |
| 8 |
[GO] |
2021―Sep―11 |
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials |
Luis Ortega-Paz, Mattia Galli, Davide Capodanno, Francesco Franchi, Fabiana Rollini, Behnood Bikdeli, et al. (+6) Roxana Mehran, Gilles Montalescot, C Michael Gibson, Renato D Lopes, Felicita Andreotti, Dominick J Angiolillo |
| 9 |
[GO] |
2021―Jun―28 |
Tocilizumab, blood cells and mild COVID-19: Delayed vascular protection by interleukin blockade? |
Liudmila Buryachkovskaya, Nikita Lomakin, Arthur Melkumyants, Julia Docenko, Victor Serebruany |
| 10 |
[GO] |
2020―May―06 |
The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19 |
Mario Enrico Canonico, Roberta Siciliano, Fernando Scudiero, Giuseppe Damiano Sanna, Guido Parodi |
| 11 |
[GO] |
2020―Apr―20 |
Anticoagulation in COVID-19 |
Bassam Atallah, Saad I Mallah, Wael AlMahmeed |
| 12 |
[GO] |
2020―Apr―08 |
Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients |
Domenico Acanfora, Marco Matteo Ciccone, Pietro Scicchitano, Chiara Acanfora, Gerardo Casucci |
| 13 |
[GO] |
2020―Apr―07 |
Might renin-angiotensin system blockers play a role in the COVID-19 pandemic? |
Allegra Battistoni, Massimo Volpe |
| 14 |
[GO] |
2020―Mar―26 |
Speculation is not evidence: antihypertensive therapy and COVID-19 |
Giovanni de Simone, Costantino Mancusi |
